Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension.

33 , 34 Therefore, as an example, a smaller decrement in the walk distance might be significant if accompanied by worse desaturation, greater oxygen requirements, a lower pulse rate recovery or an increase in the Borg dyspnea score. 35 , 36 , 37 , 38 (c) Accelerometry/actigraphy .

also in 2,428 other papers